NCT06864988进行中（未招募）3 期
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 480
- 试验地点
- 160
- 主要终点
- Mean change from baseline in BCVA ETDRS letter score at Week 52
研究概览
简要总结
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥50 years of age at time of consent
- •Treatment naïve MNV secondary to nAMD in the study eye
- •Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT), in the study eye, at the Screening Visit confirmed by the Reading Center
- •Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center
- •BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit
- •CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center
排除标准
- •Ocular Conditions:
- •MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter))
- •History of retinal detachment in the study eye
- •History of or presence of active inflammation in either eye
- •Glaucoma or intraocular hypertension requiring more than 2 topical medications for control
- •Systemic Conditions and Considerations:
- •Major illness or major surgical procedure in the 28 days prior to the Screening Visit
- •Uncontrolled blood pressure
- •Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit
- •History of autoimmune condition that may predispose to the development of uveitis
研究组 & 干预措施
4D-150 IVT (3E10 vg/eye)
Experimental
干预措施: 4D-150 IVT (3E10 vg/eye) (Biological)
Aflibercept (AFLB) 2 mg IVT
Active Comparator
干预措施: EYLEA® (aflibercept) Injection 2 mg (0.05mL) (Biological)
结局指标
主要结局
Mean change from baseline in BCVA ETDRS letter score at Week 52
时间窗: 52 Weeks
次要结局
- Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104(104 Weeks)
- Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104(104 Weeks)
- Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm(104 Weeks)
- Mean change from baseline in CST over time through Weeks 52 and 104(104 Weeks)
- Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104(104 Weeks)
研究者
研究点 (160)
Loading locations...
相似试验
已完成
3 期
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)Dry Eye Disease (DED)NCT04139798Bausch & Lomb Incorporated599
已完成
3 期
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)Dry Eye DiseaseNCT04567329Bausch & Lomb Incorporated620
已完成
3 期
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 TrialGlabellar LinesNCT05804656CKD Bio Corporation300
进行中（未招募）
1 期
A study to compare triple therapy versus dual therapy in patients with asthmaAsthmaEUCTR2016-001304-37-DEGlaxoSmithKline Research & Development Ltd2,250
进行中（未招募）
1 期
A study to compare triple therapy versus dual therapy in patients with asthmaAsthmaEUCTR2016-001304-37-PLGlaxoSmithKline Research & Development Ltd2,250